Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helga Radner

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Seminars in Arthritis and Rheumatism|April 10, 2016
Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trialDaniel H Solomon, Sara B Lee, Agnes Zak, et al.
Rheumatology (Oxford, England)|May 28, 2025
Immunoadsorption as a novel therapy for refractory idiopathic inflammatory myopathies: a retrospective observational studyKastriot Kastrati, Thomas Karonitsch, Hanien Rajab, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 18, 2017
Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled TrialDaniel H Solomon, Elena Losina, Bing Lu, et al.
Journal of Autoimmunity|March 1, 2024
Impact of muscle biopsy on the clinical decision-making process in patients with suspected idiopathic inflammatory myopathyKastriot Kastrati, Nasim Nakhost Lotfi, Marwa G Tawfik, et al.
Journal of Autoimmunity|January 27, 2023
Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseasesDaniel Mrak, Felix Kartnig, Daniela Sieghart, et al.
Annals of the Rheumatic Diseases|July 21, 2021
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunityDaniel Mrak, Selma Tobudic, Maximilian Koblischke, et al.
Frontiers in Medicine|February 27, 2023
The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccinationSelma Tobudic, Elisabeth Simader, Thomas Deimel, et al.
Clinical Chemistry and Laboratory Medicine|November 2, 2022
Preanalytical stability of SARS-CoV-2 anti-nucleocapsid antibodiesTobias Niedrist, Lisa Kriegl, Christoph J Zurl, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 12, 2022
Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workersHelga Radner, Daniela Sieghart, Anselm Jorda, et al.
Annals of the Rheumatic Diseases|August 17, 2022
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension studyDaniel Mrak, Elisabeth Simader, Daniela Sieghart, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Seminars in Arthritis and Rheumatism|April 10, 2016
Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trialDaniel H Solomon, Sara B Lee, Agnes Zak, et al.
Rheumatology (Oxford, England)|May 28, 2025
Immunoadsorption as a novel therapy for refractory idiopathic inflammatory myopathies: a retrospective observational studyKastriot Kastrati, Thomas Karonitsch, Hanien Rajab, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 18, 2017
Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled TrialDaniel H Solomon, Elena Losina, Bing Lu, et al.
Journal of Autoimmunity|March 1, 2024
Impact of muscle biopsy on the clinical decision-making process in patients with suspected idiopathic inflammatory myopathyKastriot Kastrati, Nasim Nakhost Lotfi, Marwa G Tawfik, et al.
Journal of Autoimmunity|January 27, 2023
Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseasesDaniel Mrak, Felix Kartnig, Daniela Sieghart, et al.
Annals of the Rheumatic Diseases|July 21, 2021
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunityDaniel Mrak, Selma Tobudic, Maximilian Koblischke, et al.
Frontiers in Medicine|February 27, 2023
The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccinationSelma Tobudic, Elisabeth Simader, Thomas Deimel, et al.
Clinical Chemistry and Laboratory Medicine|November 2, 2022
Preanalytical stability of SARS-CoV-2 anti-nucleocapsid antibodiesTobias Niedrist, Lisa Kriegl, Christoph J Zurl, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 12, 2022
Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workersHelga Radner, Daniela Sieghart, Anselm Jorda, et al.
Annals of the Rheumatic Diseases|August 17, 2022
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension studyDaniel Mrak, Elisabeth Simader, Daniela Sieghart, et al.
Pageof 7